Cyanovirin-N
Alternative Names: CV-NLatest Information Update: 08 Aug 2007
At a glance
- Originator National Cancer Institute (USA)
- Developer Biosyn; National Cancer Institute (USA)
- Class Antivirals; Recombinant proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 31 Dec 2006 Discontinued - Preclinical for HIV infections treatment in USA (Topical)
- 07 Feb 2006 The Contraceptive Research and Development Organisation (CONRAD) has acquired a non-exclusive licence to research and develop Biosyn's microbicide pipeline ,
- 21 Jun 2005 Data presented at the 18th International Conference on Antiviral Research (ICAR-2005)have been added to the Viral Infections pharmacodynamics section